A macrophage-nanozyme delivery system for Parkinson's disease. - Wikidata - wikimedia - TriplyDB

A macrophage-nanozyme delivery system for Parkinson's disease.

A macrophage-nanozyme delivery system for Parkinson's disease.

http://www.wikidata.org/entity/Q37179637

about

Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases Nanostructures for peroxidases Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines Nanoscale drug delivery systems and the blood-brain barrier Nanocarriers for vascular delivery of antioxidants Cell delivery of therapeutic nanoparticles GDNF-transfected macrophages produce potent neuroprotective effects in Parkinson's disease mouse model Design strategies and applications of circulating cell-mediated drug delivery systems Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.Current Experimental Studies of Gene Therapy in Parkinson's Disease Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins.The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase.Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease Novel nanomaterials for clinical neuroscience.Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.Programmed hydrolysis of nanoassemblies by electrostatic interaction-mediated enzymatic-degradation.Block Ionomer Complex Micelles with Cross-Linked Cores for Drug Delivery.SOD1 nanozyme salvages ischemic brain by locally protecting cerebral vasculature.Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles.Cell-mediated drug delivery.Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.Exosomes as drug delivery vehicles for Parkinson's disease therapy Cross-linked antioxidant nanozymes for improved delivery to CNS Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease.Blood-borne macrophage-neural cell interactions hitchhike on endosome networks for cell-based nanozyme brain delivery.Superoxide Dismutase 1 Nanozyme for Treatment of Eye Inflammation.Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.Neurodegenerative disorders and nanoformulated drug development.NanoART, neuroAIDS and CNS drug delivery.Protein-polymer nanoreactors for medical applications.Cells as delivery vehicles for cancer therapeutics.Leukocytes as carriers for targeted cancer drug delivery.Lysosomal targeting strategies for design and delivery of bioactive for therapeutic interventions.Polymer-based vehicles for therapeutic peptide delivery.Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy.Macrophage-based cell therapies: The long and winding road

P2860

Q21133553-DD6D55AC-BED9-49BA-AD2D-8A859FBB32A4 Q26782807-4070B8CB-FAD8-4EB4-837F-95427C7844CF Q26850868-0E8DE4F8-7ABB-47A7-914A-38FD61A7A8DC Q27026978-19D88696-D6F1-48EC-AC21-A06DCA6D793D Q27027067-278CBC3D-4A10-47FC-8977-A1638B02D263 Q28385606-D8958A5C-25EA-4445-9F32-2C9C99FC033C Q28543023-9289F786-031D-4F1E-9C16-0026F0DB1AC2 Q28547179-6DAE337B-CC83-4B95-B3F7-D3766343DF6D Q30387307-224DFB29-A39E-411A-B71E-00285C7B015A Q33627771-34AC2071-D9D4-4D3D-A51F-DAC5354CB6FA Q33631069-1339C3FE-1E64-4273-ABFF-022E3463F724 Q33812130-1E43EE3B-258D-4DA7-B1C7-7C7BD0EE0972 Q33831400-A4DD0958-B06A-491B-9D73-1FB5755C8B90 Q33892744-8CF4CF3B-38FF-49C2-8441-84EAC4FBABC9 Q34009532-2DD32B08-A52A-436D-9F0A-A93FD594FFAA Q34079604-4E9F95D1-C852-4049-91D8-74F3D2FE5CF1 Q34193423-136EDAAA-1A1E-48C1-B58A-EEDDB0DF7D8F Q34364190-474B3205-0539-438F-A7C8-443C5328166A Q34481558-4AECBD32-3799-4D87-BB32-81C664541B42 Q34566992-627B3C4E-27A3-4D75-9F1A-A800C1810C68 Q34709440-50F1B1D8-08A8-4D27-A7C0-BBD06F40E26E Q34797004-F3F2B669-13DF-473D-AFF6-84CD9346BB12 Q35194750-C41400CC-18BA-40BF-B9A8-A178559E467F Q35602589-6A4D74C1-36D5-4B0B-B5CF-BE494C71159F Q35664128-DC4D29CF-E6F8-4698-BEF7-BA9FD4F342C7 Q35702733-01968584-C5AD-49CE-92FC-39D7B0788B82 Q36063039-BC8BFECE-C6D6-45FD-B5D2-BF3DE2DD4762 Q36369061-FF257CA4-45C1-4858-85F3-FC813FBDC251 Q36684451-A64DAE12-2CED-4D48-9AC3-2C578FD84D15 Q36698602-53C0ADF7-F159-43EB-A89E-6DB1B3B55B78 Q37395149-42DD3909-2051-4073-9276-A271BE09F2FC Q37538771-B416C30E-5DED-4FF0-8066-A120098520AE Q37538776-5C5F3235-90DC-4A35-BCE4-C42E30340FAD Q37956493-EA67EE86-A739-48A2-AEF4-A2D9B8B4347A Q38226664-5C63377F-88B0-4FB0-A5FD-369FB6685007 Q38255704-6E992B47-8AD9-4E70-9368-551E7B709600 Q38634529-7F9C4ACA-C1AA-4B86-92B3-0178B7781E7C Q38645362-92655BE0-A453-442F-A379-577AEBABA228 Q38827940-7BC409B7-B70C-49C6-919C-41651653A0F4 Q38898549-6CB315F1-CA71-4425-9731-0E714744667F

P2860

A macrophage-nanozyme delivery system for Parkinson's disease.

http://www.wikidata.org/entity/Q37179637

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 August 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A macrophage-nanozyme delivery system for Parkinson's disease.

@en

A macrophage-nanozyme delivery system for Parkinson's disease.

@nl

type

label

A macrophage-nanozyme delivery system for Parkinson's disease.

@en

A macrophage-nanozyme delivery system for Parkinson's disease.

@nl

prefLabel

A macrophage-nanozyme delivery system for Parkinson's disease.

@en

A macrophage-nanozyme delivery system for Parkinson's disease.

@nl

P1433

Q37179637-F9682C9E-A064-4994-85D0-71CFD9A095A4

P1476

Q37179637-991764B2-B846-4856-AFD4-C9152403525E

P2093

Q37179637-201C415D-E2F8-445F-A3FF-13FCA8156C4E

Q37179637-5869A8DD-EDA7-47EC-8844-E018F217B779

Q37179637-6134C0EE-8FEE-4857-A82B-DD14158CECA4

Q37179637-730A0E1E-C497-4912-8DDD-729512EC4DE0

Q37179637-750D505A-1A4F-4B0C-BF34-AC74517F7B65

Q37179637-B9FFF94A-378D-483D-A1E1-16670CD332E5

Q37179637-C3AB208A-1211-439D-93C9-D2FA48772425

P2860

Q37179637-01634558-FCBF-4E46-A61C-A266A76F67F7

Q37179637-027693A0-55DB-4B66-AAE4-90D3D434D535

Q37179637-04420B53-13BC-4F9B-B24E-88177F2AE868

Q37179637-054C43BF-1B41-4993-B9A5-B6A03768F6A3

Q37179637-08A41DA2-559A-48AA-AAAA-A62ED5CC6B95

Q37179637-0CC274F9-E597-425B-85EC-BB3747E60F0E

Q37179637-0CEDA789-0296-4975-A8EC-9C5BAE9CAA41

Q37179637-11043A1B-C27B-4A43-A7BB-832B35E8181D

Q37179637-1109A207-EE42-4710-BBE1-53DB40E87882

Q37179637-119B2A2F-B649-4592-8B3C-2FA493C29F91

P304

Q37179637-2B16BA83-935E-4777-8870-242050870E8C

P31

Q37179637-08356E12-3401-450D-8A64-5676BC7729AA

P356

Q37179637-5061385D-3AC3-4CF4-847E-AA6F332A1FBD

P433

Q37179637-73032284-D6EE-487D-8E6B-B1FD2FE0F4A6

P478

Q37179637-3FD5438D-9C25-42EF-93B9-4FBE3056BD1D

P577

Q37179637-04EB9CE0-2A64-4CB3-A6CF-78F6F3E9D247

P5875

Q37179637-5E6D71BD-BCD1-4002-91DE-F55CD896DF43

P698

Q37179637-61300F1B-EF7C-4F06-BF09-4194F77F5F95

P921

Q37179637-62509200-687C-42C4-8983-D0E24FA7D3C6

Q37179637-CF5AEAE2-41E7-406E-8E19-DD624441203F

P932

Q37179637-C1BFE73B-9E4F-454A-80A0-49DFF006C4B9

P356

P1433

Bioconjugate Chemistry

P1476

A macrophage-nanozyme delivery system for Parkinson's disease.

@en

P2093

Alexander V Kabanov

http://www.w3.org/2001/XMLSchema#string

Ashley D Reynolds

http://www.w3.org/2001/XMLSchema#string

Elena V Batrakova

http://www.w3.org/2001/XMLSchema#string

Howard E Gendelman

http://www.w3.org/2001/XMLSchema#string

R Lee Mosley

http://www.w3.org/2001/XMLSchema#string

Shu Li

http://www.w3.org/2001/XMLSchema#string

Tatiana K Bronich

http://www.w3.org/2001/XMLSchema#string

P2860

Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs.

Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease

Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.

Interleukin-1beta -induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: a magnetic resonance study.

Reactive microgliosis.

Nanogels for oligonucleotide delivery to the brain.

A women's health issue: Alzheimer's disease and strategies for maintaining cognitive health.

Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale.

P304

1498-1506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/BC700184B

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6080721

http://www.w3.org/2001/XMLSchema#string

P698

17760417

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2677172

http://www.w3.org/2001/XMLSchema#string